| IELSG49 | Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) |
| Participants required: | 24 |
| Investigator responsible(s): | A. Stathis, D. Rossi, E. Zucca |
| Objective(s): | The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL. |
